Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report
文献类型：期刊论文
| 作者 | Gu, Xiaodong4,5,6; Wang, Wenxian5,6; Wu, Wei6,7; Zhang, Yiping5,6; Shao, Lan5,6; Santarpia, Mariacarmela8; Christopoulos, Petros1,3,9,10; Myall, Nathaniel J.2; Shi, Zhiyong5,6; Lou, Guangyuan5,6 |
| 刊名 | TRANSLATIONAL LUNG CANCER RESEARCH
 |
| 出版日期 | 2022-05-01 |
| 卷号 | 11 |
| ISSN号 | 2218-6751 |
| 关键词 | Non-small cell lung cancer (NSCLC) HIVEP1-ALK alectinib intergenic region (IGR) case report |
| DOI | 10.21037/tlcr-22-288 |
| 通讯作者 | Lou, Guangyuan(lougy@zjcc.org.cn) |
| 英文摘要 | Background: Anaplastic lymphoma kinase (ALK) fusion is an important oncogenic driver in non-small cell lung cancer (NSCLC). Reports on the intergenic region (IGR) as an ALK fusion partner are rare. Here, we report the case of a patient with advanced NSCLC harboring a human immunodeficiency virus type I enhancer binding protein 1 (HIVEP1)-ALK fusion that responded effectively to alectinib. Case Description: A 60-year-old non-smoking male was referred with a 3-month history of productive cough secondary to lung adenocarcinoma metastatic to mediastinal lymph nodes, brain, liver, and bone (T2N3M1c, stage IVB). Next-generation sequencing identified an IGR (upstream HIVEP1-) ALK fusion, and immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) results were consistent with an ALK-positive tumor. The patient was subsequently started on alectinib, with no obvious adverse reaction. After 1 month of therapy, the patient achieved significantly remission of the clinical symptoms and had led to an ongoing partial response (PR) lasting >33 months. Conclusions: Our experience highlights the efficacy of alectinib in a patient with HIVEP1-ALK fusion positive NSCLC with multiple metastases including brain disease, and the need for multiple genetic testing methods to verify the oncogenicity of ALK fusions prior to treatment. It could provide useful guidance for the treatment of similar cases in the future. |
| WOS关键词 | BRAIN METASTASES ; ALK ; CANCER ; SURVIVAL |
| 资助项目 | Zhejiang Medical and Health Science and Technology Program[2022KY644] ; Zhejiang Medical and Health Science and Technology Program[2018KY023] |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| 出版者 | AME PUBLISHING COMPANY |
| WOS记录号 | WOS:000834668600007 |
| 资助机构 | Zhejiang Medical and Health Science and Technology Program |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129259]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Lou, Guangyuan |
| 作者单位 | 1.Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany 2.Stanford Canc Inst, Div Oncol, Stanford, CA USA 3.German Ctr Lung Res DZL, Heidelberg, Germany 4.Zhejiang Chinese Med Univ, Clin Med Coll 2, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Thorac Med Oncol, 1 Banshan East Rd, Hangzhou 310022, Peoples R China 6.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou, Peoples R China 7.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 8.Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy 9.Heidelberg Univ Hosp, Thoraxklin, Dept Thorac Oncol, Heidelberg, Germany 10.Translat Lung Res Ctr, Heidelberg, Germany |
| 推荐引用方式 GB/T 7714 | Gu, Xiaodong,Wang, Wenxian,Wu, Wei,et al. Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report[J]. TRANSLATIONAL LUNG CANCER RESEARCH,2022,11. |
| APA | Gu, Xiaodong.,Wang, Wenxian.,Wu, Wei.,Zhang, Yiping.,Shao, Lan.,...&Lou, Guangyuan.(2022).Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report.TRANSLATIONAL LUNG CANCER RESEARCH,11. |
| MLA | Gu, Xiaodong,et al."Novel HIVEP1-ALK fusion in a patient with lung adenocarcinoma demonstrating sensitivity to alectinib: a case report".TRANSLATIONAL LUNG CANCER RESEARCH 11(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。